MA28081A1 - NEW ASSOCIATION OF ANTI-ATHEROTHROMBOTIC AND AN ANTIAGRAM PLAQUETTAIRE - Google Patents
NEW ASSOCIATION OF ANTI-ATHEROTHROMBOTIC AND AN ANTIAGRAM PLAQUETTAIREInfo
- Publication number
- MA28081A1 MA28081A1 MA28908A MA28908A MA28081A1 MA 28081 A1 MA28081 A1 MA 28081A1 MA 28908 A MA28908 A MA 28908A MA 28908 A MA28908 A MA 28908A MA 28081 A1 MA28081 A1 MA 28081A1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- vascular
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
7- Composition pharmaceutique selon l'une quelconque des revendications 5 ou 6 caractérisée en ce que le composé (A) est sous forme de sel de sodium. 8- Composition pharmaceutique selon l'une quelconque des revendications 5, 6 ou 7 caractérisée en ce que le clopidogrel est sous forme d'hydrogénosulfate. 9- Composition pharmaceutique selon l'une quelconque des revendications 5 à 8 caractérisé en ce que les quantités de principes actifs sont respectivement comprises entre 1 et 300 mg pour le composé (A) et 10 et 600 mg pour clopidogrel. 10- Composition pharmaceutique selon l'une quelconque des revendications 5 à 9 utile pour le traitement des maladies cardiovasculaires dans lesquelles l'activation des récepteurs TP est impliquée ainsi que pour le traitement des conséquences de ces maladies. 11-Composition pharmaceutique selon la revendication 10 utile pour le traitement du syndrome coronaire aigü, de l'angor stable ou instable, du dysfonctionnement endothélial, des maladies vasculaires liées à l'athérosclérose, à l'hypertension, au diabète et à l'insuffisance cardiaque, la prévention et le traitement des troubles du système vasculaire, cardiovasculaire ou neurovasculaire, et des troubles thromboemboliques associés notamment à l'athérosclérose, la fibrillation auriculaire, les gestes chirurgicaux invasifs en cardiologie, neurologie, pathologie vasculaire et radiologie.7- pharmaceutical composition according to any one of claims 5 or 6 characterized in that the compound (A) is in the form of sodium salt. 8. Pharmaceutical composition according to any one of claims 5, 6 or 7 characterized in that the clopidogrel is in the form of hydrogen sulfate. 9- pharmaceutical composition according to any one of claims 5 to 8 characterized in that the amounts of active ingredients are respectively between 1 and 300 mg for the compound (A) and 10 and 600 mg for clopidogrel. 10- Pharmaceutical composition according to any one of claims 5 to 9 for the treatment of cardiovascular diseases in which the activation of TP receptors is involved and for the treatment of the consequences of these diseases. Pharmaceutical composition according to claim 10 for the treatment of acute coronary syndrome, stable or unstable angina, endothelial dysfunction, vascular diseases related to atherosclerosis, hypertension, diabetes and insufficiency. cardiac, prevention and treatment of disorders of the vascular, cardiovascular or neurovascular system, and thromboembolic disorders associated in particular with atherosclerosis, atrial fibrillation, invasive surgical procedures in cardiology, neurology, vascular pathology and radiology.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0311595A FR2860436B1 (en) | 2003-10-03 | 2003-10-03 | NEW ASSOCIATION OF ANTI-ATHEROTHROMBOTIC AND AN ANTIAGRAM PLAQUETTAIRE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28081A1 true MA28081A1 (en) | 2006-08-01 |
Family
ID=34307392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28908A MA28081A1 (en) | 2003-10-03 | 2006-04-03 | NEW ASSOCIATION OF ANTI-ATHEROTHROMBOTIC AND AN ANTIAGRAM PLAQUETTAIRE |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20070054934A1 (en) |
| EP (1) | EP1677779B1 (en) |
| JP (1) | JP2007507475A (en) |
| KR (1) | KR100782246B1 (en) |
| CN (1) | CN100453075C (en) |
| AR (1) | AR046043A1 (en) |
| AT (1) | ATE409033T1 (en) |
| AU (1) | AU2004277734B2 (en) |
| BR (1) | BRPI0415043A (en) |
| CA (1) | CA2540062A1 (en) |
| CY (1) | CY1108388T1 (en) |
| DE (1) | DE602004016762D1 (en) |
| DK (1) | DK1677779T3 (en) |
| EA (1) | EA009418B1 (en) |
| ES (1) | ES2314457T3 (en) |
| FR (1) | FR2860436B1 (en) |
| GE (1) | GEP20084546B (en) |
| HK (1) | HK1093900A1 (en) |
| HR (1) | HRP20080546T3 (en) |
| MA (1) | MA28081A1 (en) |
| MX (1) | MXPA06003713A (en) |
| MY (1) | MY137953A (en) |
| NO (1) | NO20061944L (en) |
| NZ (1) | NZ545988A (en) |
| PL (1) | PL1677779T3 (en) |
| PT (1) | PT1677779E (en) |
| SI (1) | SI1677779T1 (en) |
| UA (1) | UA80220C2 (en) |
| WO (1) | WO2005032533A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05014086A (en) * | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Pharmaceutical compositions containing combined platelet aggregation inhibiting substances for use in the treatment and prevention of ischemic vascular events. |
| FR2899473B1 (en) | 2006-04-07 | 2008-06-13 | Servier Lab | USE OF ANTI-ATHEROTHROMBOTIC COMPOUND FOR OBTAINING MEDICAMENTS FOR THE TREATMENT OF VASCULAR DISORDERS |
| WO2008127682A2 (en) | 2007-04-13 | 2008-10-23 | Millennium Pharmaceuticals, Inc. | Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor |
| FR2920772B1 (en) * | 2007-09-11 | 2009-10-23 | Servier Lab | ASSOCIATION BETWEEN ANTI-ATHEROTHROMBOTICS AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2711139B1 (en) * | 1993-10-15 | 1995-12-01 | Adir | New 1,2,3,4-tetrahydronaphthalene derivatives, process for their preparation and pharmaceutical compositions containing them. |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
-
2003
- 2003-10-03 FR FR0311595A patent/FR2860436B1/en not_active Expired - Fee Related
-
2004
- 2004-01-10 UA UAA200604866A patent/UA80220C2/en unknown
- 2004-10-01 WO PCT/FR2004/002489 patent/WO2005032533A1/en active IP Right Grant
- 2004-10-01 MX MXPA06003713A patent/MXPA06003713A/en active IP Right Grant
- 2004-10-01 JP JP2006530412A patent/JP2007507475A/en active Pending
- 2004-10-01 EP EP04791453A patent/EP1677779B1/en active Active
- 2004-10-01 PL PL04791453T patent/PL1677779T3/en unknown
- 2004-10-01 KR KR1020067008071A patent/KR100782246B1/en not_active IP Right Cessation
- 2004-10-01 AR ARP040103566A patent/AR046043A1/en unknown
- 2004-10-01 DE DE602004016762T patent/DE602004016762D1/en active Active
- 2004-10-01 NZ NZ545988A patent/NZ545988A/en unknown
- 2004-10-01 AT AT04791453T patent/ATE409033T1/en not_active IP Right Cessation
- 2004-10-01 CN CNB2004800283560A patent/CN100453075C/en not_active Expired - Fee Related
- 2004-10-01 AU AU2004277734A patent/AU2004277734B2/en not_active Ceased
- 2004-10-01 GE GEAP20049368A patent/GEP20084546B/en unknown
- 2004-10-01 BR BRPI0415043-0A patent/BRPI0415043A/en not_active IP Right Cessation
- 2004-10-01 CA CA002540062A patent/CA2540062A1/en not_active Abandoned
- 2004-10-01 SI SI200430919T patent/SI1677779T1/en unknown
- 2004-10-01 PT PT04791453T patent/PT1677779E/en unknown
- 2004-10-01 MY MYPI20044026A patent/MY137953A/en unknown
- 2004-10-01 DK DK04791453T patent/DK1677779T3/en active
- 2004-10-01 ES ES04791453T patent/ES2314457T3/en active Active
- 2004-10-01 EA EA200600657A patent/EA009418B1/en not_active IP Right Cessation
- 2004-10-01 US US10/574,119 patent/US20070054934A1/en not_active Abandoned
-
2006
- 2006-04-03 MA MA28908A patent/MA28081A1/en unknown
- 2006-05-02 NO NO20061944A patent/NO20061944L/en not_active Application Discontinuation
-
2007
- 2007-01-10 HK HK07100322.2A patent/HK1093900A1/en unknown
-
2008
- 2008-09-30 CY CY20081101088T patent/CY1108388T1/en unknown
- 2008-12-03 HR HR20080546T patent/HRP20080546T3/en unknown
-
2009
- 2009-11-09 US US12/590,489 patent/US20100056564A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barnett et al. | Drugs and surgery in the prevention of ischemic stroke | |
| FR16C0019I2 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON VALSARTAN AND NEP INHIBITORS | |
| AU784426C (en) | Tissue factor antagonists and methods of use thereof | |
| MA27330A1 (en) | ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS | |
| MA28081A1 (en) | NEW ASSOCIATION OF ANTI-ATHEROTHROMBOTIC AND AN ANTIAGRAM PLAQUETTAIRE | |
| RU2000100812A (en) | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF ARTERIAL THROMBOSIS AND THE APPLICATION OF THE INHIBITOR OF THE HA HA SELF FACTOR IN SELF AND / OR IN COMBINATION WITH THE AGENT THAT PREVENTS THROMBOCY AGENTS | |
| JP2017095512A (en) | Composition for inhibition of cathepsin k | |
| Liu et al. | Calpains mediate acute renal cell death: role of autolysis and translocation | |
| CA2503211A1 (en) | Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent | |
| Shiga et al. | Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving bepridil | |
| CA2571644A1 (en) | New association of a sinus node if current inhibitor and a converting enzyme inhibitor, and the pharmaceutical compositions containing them | |
| EP1047413B1 (en) | Pharmaceutical composition comprising a specific inhibitor of aminopeptidase a, in particular ec33, for decreasing blood pressure | |
| Buchanan et al. | Effect of aspirin on hemostasis and thrombosis | |
| Goodman et al. | Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease | |
| Rabbani et al. | The role of magnesium therapy in acute myocardial infarction | |
| CN1297265C (en) | Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases | |
| Bodde | Optimization of secondary prevention and risk stratification in patients with coronary heart disease | |
| Sinnaeve | Acute ST-elevation myocardial infarction | |
| MA31624B1 (en) | USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS OR THEIR INDIRECT SEQUENCES CAUSED BY ISCHEMIA OR REPERFUSION EVENTS | |
| JP2004189711A (en) | Use of meloxicam in combination with antiplatelet for treatment of acute coronary syndrome and related condition | |
| TH82141A (en) | Tetrazole And methods of treating disorders associated with the metabolism of those substances. |